NCT04412850

Intravenous Magnesium Sulphate in Acute Ischemic Stroke

Role of Intravenous Magnesium Sulphate in Improving Clinical Outcome in Patients Suffering From Acute Ischemic Stroke

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Dow University of Health Sciences · Academic / Other
• Sex: All
• Age: 45 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

Magnesium has a neuroprotective role so the investigators aim to evaluate the role of intravenous magnesium sulphate in improving the clinical outcomes as assessed by the NIH Stroke Scale (NIHSS) in patients with acute ischemic stroke.

Conditions

• Stroke
• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Magnesium Sulfate	Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment. All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge.

Timeline

• Start date: 2020-12-01
• Primary completion: 2021-06-01
• Completion: 2021-08-01
• First posted: 2020-06-02
• Last updated: 2020-06-02